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Chronic exposure to inorganic arsenic (In-As)
is known to cause characteristic skin lesions;
cancers of the skin, bladder, kidney, and lung;
and vascular health effects [National Research
Council (NRC) 2001; World Health
Organization (WHO) 2001]. Evidence sug-
gests that In-As may also increase the risk of
diabetes, hypertension, and other internal
cancers (WHO 2001). In addition, In-As
exposure may be associated with various
reproductive and developmental effects
(Hopenhayn et al. 2003; Hopenhayn-Rich et
al. 2000; WHO 2001). Worldwide, the most
common source of human exposure is
through drinking water from sources that are
naturally high in In-As. Populations in a
number of countries have been identified as
having high exposures and elevated health
risks (WHO 2001). 
The metabolism of In-As is mainly
through methylation to monomethylarsonic
acid (MMA) and dimethylarsinic acid
(DMA). Until recently, methylation was
regarded as the main metabolic detoxiﬁcation
pathway by which the highly toxic In-As
species were converted to the less toxic and
more easily excreted methylated species [U.S.
Environmental Protection Agency (EPA)
1988; Vahter and Concha 2001). Because
most In-As, MMA, and DMA (hereafter
referred to as arsenic species) is eliminated in
the urine, the sum of urinary arsenic species
has been considered a good measure of In-As
exposure, and the relative proportion of uri-
nary species, particularly the methylated forms,
has been considered an appropriate indicator
of methylation efficiency and detoxification
capacity (Hopenhayn-Rich et al. 1996a,
1996b; Vahter 1999; Vahter and Concha
2001). Recently, this notion has been chang-
ing because of the isolation of trivalent methy-
lated species (MMA+3 and DMA+3), the
evidence that MMA+3 is a necessary intermedi-
ate in the methylation process (In-As+5 → In-
As+3 → MMA+5 → MMA+3 → DMA+5 →
DMA+3), and ﬁndings from laboratory studies
showing that trivalent methylated species, par-
ticularly MMA+3, may be more toxic than In-
As (Styblo et al. 2000, 2002). However, the
degree of tissue exposure to these intermediates
is not yet clear, trivalent MMA and DMA are
unstable in solution (e.g., urine), and the
methodology for their measurement in urine
has only recently been developed (Del Razo et
al. 2001). Issues of sampling and stability of
species during storage, as well as inter-
individual variation in the stability of trivalent
species, affect the differentiation and the rela-
tive proportions of MMA+3 and DMA+3 (Del
Razo et al. 2001). Therefore, further develop-
ment is needed before separation of all urinary
species becomes a common monitoring tool in
epidemiologic studies.
The relative distribution of urinary In-As,
MMA, and DMA is still considered an ade-
quate indicator of methylation capacity after
exposure to In-As, although the interpretation
of the ﬁndings in terms of detoxiﬁcation ver-
sus toxification is currently an area of active
investigation (Styblo 2002; Vahter and
Concha 2001). Under the detoxification
hypothesis of In-As through methylation, a
relatively higher proportion of methylated
species, particularly DMA, in the urine has
been viewed as an indicator of higher methy-
lation capacity or efficiency. Later studies of
various populations exposed to contrasting
arsenic exposures found that a relatively small
variability could be attributed to exposure, but
other factors also contributed to urinary distri-
bution of arsenic metabolites, such as age,
smoking, and genetic susceptibility (Vahter
1999). In addition to these factors, several
studies have reported gender differences in the
distribution of arsenic metabolites, with
women having a higher percentage of methy-
lated metabolites compared with men, even
after adjusting for other factors. A study in the
Atacama Desert in Chile compared methyla-
tion patterns in residents from two villages
with distinct arsenic water concentrations
(600 µg/L vs. 15 µg/L). In both locations,
women were found to have lower percentages
of In-As and higher percentages of DMA
compared with men (Hopenhayn-Rich
1996a, 1996b). Studies in Taiwan (Hsueh et
al. 1998), Finland (Kurttio 1998), and the
United States (Kalman et al. 1990) found
similar gender differences.
A study conducted among women living
at high altitude in the Andean region of
Argentina (Concha et al. 1998) reported on
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Chronic exposure to inorganic arsenic (In-As) from drinking water is associated with different health
effects, including skin, lung, bladder, and kidney cancer as well as vascular and possibly reproductive
effects. In-As is metabolized through the process of methylation, resulting in the production and
excretion of methylated species, mainly monomethylarsenate (MMA) and dimethylarsenate (DMA).
Because a large percentage of the dose is excreted in urine, the distribution of urinary In-As, MMA,
and DMA is considered a useful indicator of methylation patterns in human populations. Several
factors affect these patterns, including sex and exposure level. In this study, we investigated the pro-
ﬁle of urinary In-As, MMA, and DMA of pregnant women. Periodic urine samples were collected
from early to late pregnancy among 29 pregnant women living in Antofagasta, Chile, who drank tap
water containing 40 µg/L In-As. The total urinary arsenic across four sampling periods increased
with increasing weeks of gestation, from an initial mean value of 36.1 to a ﬁnal value of 54.3 µg/L.
This increase was mainly due to an increase in DMA, resulting in lower percentages of In-As and
MMA and a higher percentage of DMA. Our ﬁndings indicate that among women exposed to mod-
erate arsenic from drinking water during pregnancy, changes occur in the pattern of urinary arsenic
excretion and metabolite distribution. The toxicologic signiﬁcance of this is not clear, given recent
evidence suggesting that intermediate methylated species may be highly toxic. Nevertheless, this
study suggests that arsenic metabolism changes throughout the course of pregnancy, which in turn
may have toxicologic effects on the developing fetus. Key words: arsenic, arsenic metabolism, arsenic
methylation, Chile, pregnancy, urinary arsenic. Environ Health Perspect 111:1888–1891 (2003).
doi:10.1289/ehp.6254 available via http://dx.doi.org/ [Online 4 September 2003]the effect of pregnancy on arsenic methylation.
Ten pregnant women provided urine samples
for arsenic speciation analysis shortly before giv-
ing birth and then at 2.8 weeks, 2.5 months,
and 4.4 months postpartum. A higher propor-
tion of methylated species was observed during
late pregnancy compared with after delivery
(87%, 78%, 64%, and 69% DMA, respec-
tively). These results led us to investigate the
distribution of urinary arsenic species (In-As,
MMA, and DMA) to evaluate potential
changes in arsenic methylation patterns during
the course of pregnancy. For this purpose, we
measured arsenic species in sequential urine
samples obtained during pregnancy from
women exposed to moderately elevated arsenic
levels in drinking water.
Materials and Methods
In the present methylation study we examined
a subgroup of women who participated in a
pregnancy cohort study investigating several
reproductive outcomes in relation to arsenic
exposure from drinking water. A detailed
description of the parent study has been pub-
lished (Hopenhayn 2003). For the purpose of
the present study, a brief description of the
overall methodology follows.
The cohort study enrolled more than 900
women in two Chilean cities: Antofagasta,
with arsenic water levels averaging around
40 µg/L, and Valparaiso, with low exposure
to arsenic in water (< 1 µg/L). Women were
eligible to enter the study if they were at least
18 years of age, were between 16 and
36 weeks of gestation, and used tap water for
drinking and cooking purposes. All women
agreed to participate in an in-person interview
that provided information regarding their
sociodemographic characteristics, dietary and
other lifestyle habits, ﬂuid consumption, exer-
cise, medical history, and other topics.
Cohort participants provided a urine sample
at entry into the study, which took place at
one of their regularly scheduled prenatal
clinic appointments. The participants were
recruited from three public health clinics in
Antofagasta and two in Valparaiso.
A subgroup of 29 women from Antofagasta
enrolled in the pregnancy cohort study was
selected to also participate in this study. The
selection of women invited into this study was
based on their entering the cohort investigation
relatively early in gestation, but otherwise the
group was a convenience sample attending one
of the three Antofagasta clinics used in the
overall study. Participants in this study agreed
to provide additional urine samples throughout
their pregnancy at relatively regular intervals,
about a month apart. To obtain their samples,
they were contacted by a midwife who was on
the cohort study staff and was also assigned to
the methylation study sample collection.
Sequential urine samples were obtained either
at later prenatal visits or at the participants’
home, depending on whether the midwife was
able to be at the clinic when the study partici-
pants had their prenatal appointments. Each
woman provided three to five samples,
depending on the weeks of gestation at enroll-
ment and on practical considerations. Because
most women (n = 27) provided at least four
samples, for the sake of consistency we selected
up to four per participant for laboratory analy-
sis. For women who had provided ﬁve samples,
we used the ﬁrst and last, plus two additional
ones so that the time spacing between any two
samples was similar. For the purpose of the
analysis presented here, we excluded two
women for whom we obtained only three sam-
ples and one woman who had very low total
arsenic concentration (2.4 µg/L, with nonde-
tectable levels of both MMA and DMA).
The study protocol was reviewed and
approved by the University of Kentucky
Institutional Review Board and by the partici-
pating Chilean institutions. The women partic-
ipating in this study signed two consent forms:
one for the overall cohort study and one for the
added participation in this methylation study.
The sample collection included spot urine
samples voided into a plastic cup, which was
immediately poured into two 30-mL propylene
bottles. These were placed promptly on ice
until they were transferred to a –20°C freezer
later the same day. After all the samples were
collected, they were shipped to the University
of Washington, where they were analyzed by
batch hydride generation cryogenic trapping
and atomic absorption spectophotometry
(Kalman 1988). The laboratory personnel were
unaware of the identity of the study subjects
and the timing of pregnancy of each sample.
The quantitation limits for the arsenic species
analyzed were 0.2 ppb for In-As and MMA and
0.4 ppb for DMA. Quality control analysis
included two blanks per batch, benchmark con-
trol samples before each batch and every ﬁve
samples, and replicate analysis on 10% of the
samples. The maximum allowable control sam-
ple variation permitted was 15%, and the aver-
age variability for each species was around
10%. Creatinine measurements were also per-
formed on all samples to adjust the arsenic
concentration to the creatinine content.
As explained above, the women included
in this methylation study were part of a larger
reproductive study that collected data for
many demographic and personal characteris-
tics of participants. For this report, we present
only the general characteristics of the sub-
group and concentrate mainly on their
methylation proﬁle throughout pregnancy.
We used univariate analyses to describe
general demographic, lifestyle, and pregnancy
characteristics of the study group. The four
urine samples analyzed per woman were
labeled sequentially as S1, S2 , S3, and S4, with
S1 denoting the ﬁrst sample and S4 denoting
the last one. The corresponding week of ges-
tation at which each sample was obtained was
derived from the date of sample collection
and an algorithm developed to estimate the
gestational age at birth for the entire cohort
study (Hopenhayn et al. 2003). Briefly, the
algorithm was based on comparisons among
three measures: date of last menstrual period
(LMP), ultrasound during pregnancy, and
clinical examination of the infant at birth.
The LMP was the basis for the determination
of weeks of gestation for 92% of the overall
cohort participants, and similarly, for 90% of
the 26 women in this methylation study.
We calculated the total urinary In-As
metabolites (Tot-As) by adding across the three
species measured (In-As, MMA, and DMA)
and deriving the relative proportions of each
species. We used graphical representation to
examine the distribution of metabolites and
the Tot-As for the four sampling periods across
pregnancy. We assessed differences across the
groups by one-way analyses of variance and by
nonparametric test for trend across ordered
groups (Cuzick 1985). Statistical analyses were
performed using SAS software (SAS Institute
Inc., Cary, NC, USA) and STATA (Stata
Corporation, College Station, TX, USA).
Results
Table 1 presents selected characteristics of
the present study group, including age, par-
ity, weight gain, and education, among others.
In general, the women who participated in
this methylation study, as characterized in
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Table 1. General characteristics of the study group.
Characteristic No. Frequency (%)
Education
None or primary school 9 35
Middle school 12 46
Post middle school 5 19
Monthly income (in Chilean pesos)a
$0–200,000 16 62
≥ $200,001 10 38
Parity
No birth  9 35
18 3 1
2 6 23
≥ 33 1 2
Race
Indigenous 5 19
Nonindigenous 21 81
Kessnerb
Inadequate 1 4
Intermediate 6 24
Adequate 18 72
Tobacco smoking
No 22 85
Yesc 41 5
Maternal age (years) 26 23.7 ± 5.5d
Weight gain (kg) 23 11.3 ± 4.7d
Weeks of gestation at ﬁrst visit 25 9.9 ± 3.4d
aDuring study period, $1 U.S. was ~ 400 Chilean pesos.
bIndex of prenatal care. cRange, 0.14–2.0 cigarettes per day.
dValues shown are mean ± SD.Table 1, were similar to the overall cohort
participants in Antofagasta, from where they
were subsampled (Hopenhayn et al. 2003).
Most had been pregnant before (65% had a
previous birth), started prenatal care ade-
quately early (mean gestation at ﬁrst prenatal
visit, 9.9 weeks), had adequate prenatal care
(72%), and did not have post-high school
education (19% went to college). Only four
women reported smoking during pregnancy,
and the number of cigarettes smoked per day
was low (0.14–2.0/day).
Table 2 summarizes the weeks of gestation
of the study participants at each of the four
sampling periods, and the corresponding
Tot-As, urinary creatinine, and total creatinine-
adjusted arsenic measurements. Although the
number of weeks of gestation across the differ-
ent sampling periods slightly overlapped, the
95% conﬁdence intervals of the means indicate
that they represent quite distinct periods
(18.6–20.6, 25.5–26.5, 30.2–31.6, 34.8–36.5
weeks). The sampling periods showed a steady
increase in the weeks of gestation from S1 to
S4, starting at < 20 weeks and ending around
36 weeks, thus covering most of the second
half of pregnancy. This time frame corresponds
to the period where most fetal growth and
maturation, as well as maternal physical
changes, take place (a pregnancy is considered
full term if delivery occurs at ≥ 37 completed
weeks, with 40 weeks being used for estimation
of a woman’s expected due date).
The mean Tot-As (sum of species) levels
show a clear increasing trend across preg-
nancy, with S4 having an overall mean 51.2%
greater than S1 (from 36.1 to 54.3 µg/L; Table
2). The creatinine-adjusted values showed a
similar trend, with an even steeper gradient
(from 35.6 to 63.5 µg As/g creatinine). The
medians show a similar effect, increasing from
30.3 to 61.7 µg As/g creatinine.
Table 2 also presents the percentage of
In-As, percentage of MMA, percentage of
DMA, and MMA:DMA for each of the four
sampling periods. The mean proportion of In-
As decreased by 44.1% from the S1 to S4
(from 11.8% to 8.1%). The proportion of
MMA also decreased steadily (from 7.3% to
5.6%), and the proportion of DMA corre-
spondingly increased (from 80.9% to 86.3%).
This resulted in a decrease of the MMA:DMA
ratio (from 0.095 to 0.066). The tests for
trend produced signiﬁcant results for Tot-As as
well as for each of the metabolites analyzed
across the four time periods. In addition to
the trend of the group overall, we observed a
decrease in percentage of In-As and an
increase in percentage of DMA in most of the
study subjects (22 of the 26). However, the
change in Tot-As was mostly accounted for
by the increases in DMA (which changed
from a mean of 30.2 µg/L for S1 to 46.9 µg/L
for S4; compare with the change in In-As
from 3.8 µg/L to 4.4 µg/L and in MMA from
2.1 µg/L to 3.0 µg/L). Correspondingly, most
of the change in the relative distribution of
metabolites was due to the increase in DMA.
In Figure 1 we present the decrease
observed for the interindividual variability in
the proportions of In-As, MMA, and DMA
across pregnancy (S1–S4).
It is also interesting that the two partici-
pants with the highest percentages of In-As in
S1 (who also had the highest percentages of
MMA and lowest percentages of DMA) are
the two women who reported smoking one or
two cigarettes per day. Aside from this obser-
vation, we did not find other variables to
noticeably affect the distribution of arsenic
urinary metabolites, such as month of the year
sample was taken (to examine seasonal varia-
tions), maternal age, weight gain, or education
(analysis not shown).
Discussion
The results of this study indicate that, among
women exposed to arsenic from drinking water,
changes occur in the pattern of arsenic excre-
tion and metabolite distribution during the
course of pregnancy. These changes are likely to
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Table 2. Gestational weeks, creatinine, and arsenic species for each sampling period. 
Tot-As adjusted
Gestational Tot-As for creatinine (µg/g)
age (weeks) (µg/L) Mean ± SD Median Percent In-As Percent MMA Percent DMA MMA:DMA
Sample 1 19.6 ± 2.4 36.1 ± 24.6 35.6 ± 19.6  30.3 11.8 ± 5.1 7.3 ± 3.4 80.9 ± 7.9 0.10 ± 0.06
Sample 2 26.0 ± 1.3 45.2 ± 27.5 52.5 ± 29.8  42.3 9.6 ± 3.6 6.1 ± 2.4 84.3 ± 5.7 0.08 ± 0.04
Sample 3 30.9 ± 1.8 54.2 ± 28.9 60.0 ± 16.4  58.5 9.5 ± 5.1 5.9 ± 2.1 84.6 ± 6.0 0.07 ± 0.03
Sample 4 35.7 ± 2.0 54.3 ± 21.9 63.5 ± 19.4  61.7 8.1 ± 2.7  5.6 ± 1.8  86.3 ± 3.9 0.07 ± 0.02
p-Value (test for trend) — < 0.01 < 0.01 0.01 0.02 0.01 0.01
Values shown are mean ± SD except where noted.
Figure 1. Distribution of the percentages of (A) In-As, (B) MMA, and (C) DMA in urine, at the ﬁrst (S1) and
last (S4) sampling periods, for all the study participants.
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0represent changes in arsenic metabolism. The
Tot-As levels systematically increased, mainly
due to a rise in DMA concentration. In turn,
this also changed the relative distribution of
arsenic species, decreasing the percentage of
In-As and MMA and increasing the propor-
tion of DMA, as well as decreasing the
MMA:DMA ratio.
It is not clear why the Tot-As concentration
increased. It is possible that the exposure dose
increased if the women in the study consumed
more tap water–based drinks as their preg-
nancy progressed. Because we did not take
repeated dietary or ﬂuid consumption histories
at the time of each urine sampling, we cannot
evaluate potential changes in total fluid or
arsenic intake. However, examination of the
entire pregnancy cohort of the parent study,
which had a much larger study size and a wider
range in weeks of gestation at entry into the
study, did not show women interviewed later
in pregnancy (gestation ≥ 30 weeks) reporting
higher consumption of water-based fluids
compared with women interviewed earlier in
pregnancy (gestation ≤ 20 weeks).
Because the Tot-As increase was mainly
due to an increase in total DMA, it is possible
that with the progression of pregnancy there is
an induction of methylation (Vahter et al.
1995), which facilitates arsenic excretion
(Concha et al. 1998; Vahter and Concha
2001). Given all the hormonal and other
changes that occur throughout pregnancy
(e.g., in fluid volume and distribution), it is
feasible that these may affect the metabolism
of arsenic. This hormonal hypothesis has some
support in the gender differences observed in
the proﬁle of urinary arsenic species. Another
study in Chile found that women had a
greater proportion of methylated metabolites
compared with men, particularly DMA (3.5%
difference), even after controlling for other
factors such as age, smoking, and exposure
level (Hopenhayn-Rich et al. 1996b). Gender
differences in the distribution of urinary
arsenic metabolite distribution were also
reported in other arsenic studies in Finland
(Kurttio et al. 1998), Taiwan (Hsueh et al.
1998), and the United States (Kalman et al.
1990), although the magnitude of the differ-
ences varies and the presentation of results
does not allow direct comparisons.
It is also possible that during pregnancy
there is an increased release of tissue-bound
arsenic, as DMA, or as In-As or MMA, which
is further methylated and excreted as DMA.
Individuals exposed to high arsenic levels who
were given an arsenic-chelating agent (2,3-
dimercaptopropane-1-sulfonic acid) showed a
quick increase in the concentration of urinary
arsenic, particularly methylated species
(Aposhian et al. 1997), supporting the
hypothesis that arsenic is bound to tissues and
can be released through chemical induction.
The activity of endogenous methylases in
human placenta increased steadily with weeks
of gestation, suggesting that increased forma-
tion of methyltransferases might occur during
pregnancy (Paik et al. 1991). Therefore, there
is some empirical support for the induction of
methylation during pregnancy. However, it is
not clear whether the observed results reﬂect
an increase in the methylation and excretion
of arsenic from current exposure, or from
release of arsenic bound to tissues, or both.
It remains to be investigated whether this
increased excretion of arsenic, and in particular
of methylated metabolites, can be viewed as an
enhanced detoxification process or as an
increased risk of exposure to highly toxic inter-
mediate trivalent methylated arsenicals.
Concha et al. (1998) obtained urine samples
from infants shortly after birth and found they
had an average of 90% DMA, similar to the
87% of the mothers. It would be interesting to
investigate the correlation of urinary total
arsenic and the methylation proﬁle of mothers
in pregnancy with those of their infants.
Previous studies of the distribution of
arsenic metabolites in urine have consistently
found large interindividual variability across
different populations and exposure levels.
Interestingly, in this study we observed a
decrease in interindividual variation among
the study subjects as pregnancy progressed
towards full term. In particular, the highest
percentages of In-As and MMA in earlier
pregnancy disappeared, as the lower percent-
ages of DMA diminished. We have no expla-
nation for this ﬁnding at this time. Although
the size of our study was relatively small, hav-
ing repeated measures of the same individuals
across time reduces some of the problems asso-
ciated with interindividual variability and
makes comparison possible across repeated
periods.
To our knowledge, this is the ﬁrst study in
humans to investigate changes in arsenic
methylation during pregnancy. Concha et al.
(1998) compared full-term pregnancy with
postpartum patterns of urinary arsenic species.
Although their comparison covered different
time periods than ours, the results are consis-
tent in showing highest total arsenic excretion
and percentage of DMA shortly before deliv-
ery, with an apparent return to normal
metabolite distribution after the postpartum
period. The urine samples from the newborns
of these women had a similar metabolite distri-
bution to that of the mothers before delivery
(9.2% In-As, 90% DMA), but the correlation
between mothers and infants was not given.
To give a complete description of how preg-
nancy affects the arsenic methylation process, a
study covering the entire pregnancy period, the
postpartum period, and the newborn infant is
warranted. Given the changes in methylation
patterns found throughout the second half of
pregnancy, levels in full-term newborns may
also differ from premature infants, which could
potentially reflect different arsenic species
exposure and metabolism.
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